Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma

Chinese PLA General Hospital480 enrolled

Overview

This study evaluates the efficacy of clinical nutrition to treat lung neoplasms and breast carcinoma.We estimate there will be 480 patients accepted.120 patients will receive GLSE compound,120 patients will recrive Maitake mushroom extract compound,120 patients will recrive Rinseng compound,and 120 patients will be as blank countrol group.Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma

GLSE compound、Maitake mushroom extract compound and Rinseng compound have different mechanism on enhancing immunity.This clinicaltrial compare them the immune effect in the progress of treating lung neoplasms and breast carcinoma.Within the 42 days,we will abide by the plan to evaluate the immunity enhancement by monitoring mmune effector molecules.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

SINGLE

Enrollment

480

Conditions

Lung Neoplasms Breast Neoplasms

Interventions

GLSE compoundDRUG

Maitake mushroom extract compoundDRUG

Ginseng compoundDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * lung cancer and breast cancer patients confirmed by surgery pathology; * ECOG physical stamina score of 0\~3 points; * Expected lifetime \> 3 months; * Need to receive radiation and chemotherapy; * Heart, liver and kidney function and blood picture is normal,WBC≥4×109/L, neutrophil count≥ 2 x 109 / L,platelet count≥100×109/L, hemoglobin≥100 g/L; * To follow-up, good adherence Exclusion Criteria: * Allergic to text drug; * Pregnancy or lactation women; * Suffering from mental illness of not easy to control, * Have serious mental or cognitive dysfunction; * Can not comply with the experimental scheme or can't cooperate with the follow-up; * The patients who are unfavorable to the subject.

Locations (1)

PLA general hospital

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

T-lymphocyte cell subsets

T-lymphocyte cell subsets contains CD3+、CD4+、CD8+、CD28-、CD28+、CD4+CD25+、HLADR+、HLADR-,measured these cells concentration level

Time frame: three mouths

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.